Bromocriptine for Heart Weakness in Women 18-50
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests a medicine called bromocriptine to see if it helps women with a weak heart muscle (dilated cardiomyopathy). It is for women between 18 and 50 whose heart weakness was found recently or is caused by blocked arteries, and who are not pregnant or planning pregnancy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 50 years old.
- You have a type of heart muscle weakness (dilated cardiomyopathy) that is either new or caused by blocked heart arteries.
- You do not have other serious heart conditions like valve problems, congenital defects, or high blood pressure-related heart disease.
- You are not pregnant, planning pregnancy, breastfeeding, and have not had heart failure after a past pregnancy.
- Your kidney function is normal (creatinine level below 1.4 mg/dL).
- You have never had a bad reaction to bromocriptine and are willing to take part in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether bromocriptine improves health outcomes in people recently diagnosed with peripartum cardiomyopathy (a weakened heart during late pregnancy or soon after delivery). You may be asked about timing after childbirth, heart strength tests, and whether you plan to keep breastfeeding.
This trial tests whether adding metoprolol (a beta-blocker) to usual care can prevent or slow cardiomyopathy (heart muscle weakness) in people with Duchenne muscular dystrophy (DMD). It also checks for safety, especially effects on heart rate and rhythm.
This early-stage study tests DYNE-101 to see how safe it is and whether it can improve measurable muscle function in people with myotonic dystrophy type 1 (DM1). You may be asked to do several walking and strength tests and undergo heart and breathing screening measurements.
This trial tests a once-daily drug called mexiletine PR to see if it can help reduce muscle stiffness (myotonia) in people with myotonic dystrophy type 1 or 2. It may be a good option if you have a confirmed genetic diagnosis and are at least 16 years old.
This study looks at people who have been newly diagnosed with heart failure to find rare forms of heart muscle disease (cardiomyopathy) early and start the right treatment. It uses advanced heart imaging (CMR) and requires that you have not had heart problems before.
This trial tests a medication (amlodipine) that relaxes blood vessels and muscle tissues to see if it can improve hand grip strength and muscle function in adults with myotonic dystrophy type 1. It may help if you have moderate muscle weakness and slow hand opening.
Hear when a new Dilated Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.